Literature DB >> 32089158

The Characteristics of Intestinal-Barrier Damage in Rats With IgA Nephropathy.

Nan Zhou1, Ying Shen1, Lirong Fan2, Qiang Sun1, Canxing Huang3, Jing Hao2, Jingchao Lan4, Huimin Yan5.   

Abstract

BACKGROUND: Intestinal-barrier damage plays an important pathogenic role in immunoglobulin A nephropathy (IgAN). In this study, we explored the characteristics of the intestinal barrier in rats with IgAN.
MATERIALS AND METHODS: We randomly divided 17 Sprague Dawley (SD) male rats into a normal control group (NC; n = 9) and an IgAN model group (n = 8). Feces in the distal ileum were taken for intestinal-microbiota 16sDNA sequencing. We also took a segment of terminal ileum to analyze intestinal morphology and to detect mRNA and protein expression of the tight-junction proteins zonula occludens-1 (ZO-1) and occludin (OCLN), as well as of mucin 2 (MUC2). We then measured levels of serum diamine oxidase (DAO) and D-lactic acid (D-LA), the biomarkers of intestinal permeability.
RESULTS: Compared with the NC group, mRNA expression levels of ZO-1 (t = 4.216, P = 0.0007), OCLN (t = 2.413, P = 0.029) and MUC2 (t = 0.859, P < 0.0001) were significantly decreased in the IgAN model group. Protein expression of ZO-1 (t = 7.349, P < 0.0001) and OCLN (t = 6.367, P < 0.0001) was also decreased in the IgAN model group. Conversely, serum DAO (t = 3.758, P = 0.0024) and D-LA (t = 2.246, P = 0.0427) levels increased in this group. At the genus level, the relative abundance of Ruminococcus2 (P = 0.0086) was increased in the IgAN model group.
CONCLUSIONS: Decreased expression of ZO-1, OCLN and MUC2, plus intestinal-microbiota dysbiosis, are associated with intestinal-barrier damage in IgAN rats.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Immunoglobulin A nephropathy; Intestinal microbiota; Intestinal mucosal immune system; Mucin; Tight-junction protein

Mesh:

Year:  2019        PMID: 32089158     DOI: 10.1016/j.amjms.2019.11.011

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  7 in total

Review 1.  Advances in the role and mechanism of zonulin pathway in kidney diseases.

Authors:  Jie Yu; Ying Shen; Nan Zhou
Journal:  Int Urol Nephrol       Date:  2021-01-11       Impact factor: 2.370

2.  Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice Model.

Authors:  Vincenzo Di Leo; Patrick J Gleeson; Fabio Sallustio; Carine Bounaix; Jennifer Da Silva; Gesualdo Loreto; Sanae Ben Mkaddem; Renato C Monteiro
Journal:  J Pers Med       Date:  2021-04-16

3.  Huangkui Capsule in Combination with Leflunomide Improves Immunoglobulin A Nephropathy by Inhibiting the TGF-β1/Smad3 Signaling Pathway.

Authors:  Shuwen Pei; Yan Li
Journal:  Clinics (Sao Paulo)       Date:  2021-12-10       Impact factor: 2.365

4.  Metabolic Dysfunctions of Intestinal Fatty Acids and Tryptophan Reveal Immuno-Inflammatory Response Activation in IgA Nephropathy.

Authors:  Hongwei Wu; Donge Tang; Manhua Yun; Haiping Liu; Shaoxing Huang; Chen Yun; Berthold Hocher; Xinzhou Zhang; Fanna Liu; Lianghong Yin; Yong Dai
Journal:  Front Med (Lausanne)       Date:  2022-02-03

5.  The Diagnostic and Predictive Significance of Immune-Related Genes and Immune Characteristics in the Occurrence and Progression of IgA Nephropathy.

Authors:  Jian-Bo Qing; Wen-Zhu Song; Chang-Qun Li; Ya-Feng Li
Journal:  J Immunol Res       Date:  2022-04-28       Impact factor: 4.493

6.  Gut Dysbiosis and Intestinal Barrier Dysfunction Promotes IgA Nephropathy by Increasing the Production of Gd-IgA1.

Authors:  Yuyan Tang; Yifan Zhu; Haidong He; Yinshun Peng; Ping Hu; Jiajun Wu; Weiqian Sun; Ping Liu; Yong Xiao; Xudong Xu; Minggang Wei
Journal:  Front Med (Lausanne)       Date:  2022-07-07

7.  Gut microbiota changes and biological mechanism in hepatocellular carcinoma after transarterial chemoembolization treatment.

Authors:  Chao-Fan Bian; Ying Wang; Ao Yu; Lulan Fu; Ding Zhang; Wenzhi Zhu; Weifu Lv
Journal:  Front Oncol       Date:  2022-10-04       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.